Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Recurrence Score on Adjuvant Treatment Decisions and Tumor Cell Dissemination in Estrogen-receptor Positive and HER2 Negative Patients With Early Breast Cancer

NCT03961880 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT03961880
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03961880 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Recurrence Score on Adjuvant Treatment Decisions and Tumor Cell Dissemination in Estrogen-receptor Positive and HER2 Negative Patients With Early Breast Cancer
Lead sponsor
University Hospital Tuebingen
Phase
Observational
Overall status
Completed
Start date
March 1, 2019
Completion date
June 30, 2025
Enrollment
270 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer female